Clin Mol Hepatol > Volume 27(1); 2021 > Article |
|
R.N.A model (-) (n=1,396) | R.N.A. model (+) (n=125) | P-value | |
---|---|---|---|
Male gender | 675 (48.4) | 74 (59.2) | 0.02 |
Age (years) | 58.9±13.3 | 58.6±14.8 | 0.27 |
Patient source | <0.001 | ||
Hepatology department | 1,139 (81.6) | 68 (54.4) | |
Non-hepatology department* | 257 (18.4) | 57 (45.6) | |
Diabetes | 233 (16.7) | 22 (17.6) | 0.79 |
Hypertension | 469 (33.6) | 50 (40.0) | 0.15 |
Cardiovascular disease | 44 (3.2) | 6 (4.8) | 0.30 |
Cerebrovascular disease | 80 (5.7) | 8 (6.4) | 0.76 |
White blood cell (/mm3) | 5,969±1,931 | 6,199±2,228 | 0.41 |
Hemoglobin (g/dL) | 13.8±1.8 | 13.5±1.9 | 0.32 |
Platelet count (×1,000/mm3) | 203±70 | 198±77 | 0.60 |
AST (IU/L) | 57.0±44.9 | 61.4±41.8 | 0.41 |
ALT (IU/L) | 66.6±70.6 | 74.4±63.9 | 0.34 |
Creatinine (mg/dL) | 1.27±1.79 | 1.14±1.22 | 0.41 |
HCV RNA† (log IU/mL) | 5.69±1.13 | 5.48±1.23 | 0.18 |
HCV genotype 1†, n/N (%) | 493/948 (52.0) | 54/100 (54.0) | 0.70 |
DAA regimen‡ | <0.001 | ||
EBR/GZR | 156 (17.2) | 1 (1.2) | |
SOF/LDV | 311 (34.2) | 0 (0.0) | |
GLE/PIB | 304 (33.5) | 32 (38.6) | |
SOF/VEL | 137 (15.1) | 50 (60.2) |
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
HCV, hepatitis C virus; R.N.A. model, HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DAA, direct-acting antiviral; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; LDV, ledipasvir; GLE, glecaprevir; PIB, pibrentasvir; VEL, velpatasvir.
* Including Division of Infectious Diseases (n=54), Department of Otolaryngology (n=53), Department of Psychiatry (n=49), Department of Surgery (n=43), Division of Nephrology (n=31), Division of Endodontics and Operative Dentistry (n=18), Division of Pulmonary Medicine (n=15), Department of Family Medicine (n=13), and others (n=38).
R.N.A. model (-) | R.N.A. model (+) | P-value | |
---|---|---|---|
RNA testing in anti-HCV+ patients | 84.8% (1,184/1,396) | 100.0% (125/125) | <0.001 |
Hepatology department | 98.7% (1,124/1,139)* | 100.0% (68/68) | 0.999 |
Non-hepatology department | 23.3% (60/257)* | 100.0% (57/57) | <0.001 |
HCV genotyping in HCV RNA+ patients | 98.9% (938/948) | 100.0% (100/100) | 0.61 |
Hepatology department | 99.1% (922/930) | 100.0% (54/54) | 0.999 |
Non-hepatology department | 88.9% (16/18) | 100.0% (46/46) | 0.08 |
Treatment rate in HCV RNA+ patients | 95.8% (908/948) | 83% (83/100) | <0.001 |
Hepatology department | 97.1% (903/930)* | 96.1% (49/51)†,‡ | 0.66 |
Non-hepatology department | 27.8% (5/18)* | 73.9% (34/46)† | 0.001 |
HCV treatment uptake§ | 81.2% | 83.0% | 0.85 |
Hepatology department | 95.8% | 96.1% | 0.76 |
Non-hepatology department | 6.4% | 73.9% | <0.001 |
HCV, hepatitis C virus; R.N.A. model, HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system.